Acadia Pharmaceuticals | ACAD - 销售收入



金融业
股票价格
USD
资产
USD 1.61B
现金及等价物
USD 851.46M
销售成本
USD 24.79M
流动资产
USD 1.1B
流动负债
USD 305.52M
债务
USD 52.19M
EBIT
USD -4.62M
EBITDA
USD 20.32M
员工
653
EPS每股收益
USD 0.02
股本和储备
USD 1.25B
销售毛利
USD 243.27M
债务利息支出
USD 0
利息收入
USD 8.33M
贷款资金
USD 0
市值
USD 4.36B
净收入
USD 3.64M
营业费用
USD 272.68M
营业利润
USD -4.62M
普通股股本
USD 169.18M
PE价格收益
10.08
税前利润
USD 3.98M
销售收入
USD 268.06M
销售和管理费用
USD 160.79M
股票
USD 31.57M
贸易债权人
USD 12.25M
应收帐款人
USD 148.38M


销售 更改 日
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
ALKERMES USD 496.01M 103.1M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 766M 109M 2026-03
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Cara Therapeutics USD 2.57M 1.11M 2025-03
Corcept Therapeutics USD 256.15M 91.25M 2026-06
Cytokinetics USD 19.35M 1.59M 2026-03
Eisai JPY 205.43B 14.51B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Incyte USD 1.67B 400M 2026-06
J&J USD 25.31B 1.21B 2026-06
Moderna USD 100M 289M 2026-06
Neurocrine Biosciences USD 959M 148M 2026-06
Pfizer USD 14.5B 3.08B 2026-03
Prothena USD 51.08M 51.06M 2026-03
PTC Therapeutics USD 361M 88M 2026-06
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 2.99B 200M 2026-03